EP1098652A2 - Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound - Google Patents

Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound

Info

Publication number
EP1098652A2
EP1098652A2 EP99939972A EP99939972A EP1098652A2 EP 1098652 A2 EP1098652 A2 EP 1098652A2 EP 99939972 A EP99939972 A EP 99939972A EP 99939972 A EP99939972 A EP 99939972A EP 1098652 A2 EP1098652 A2 EP 1098652A2
Authority
EP
European Patent Office
Prior art keywords
meiosis
compound
increasing
use according
hypoxanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99939972A
Other languages
German (de)
French (fr)
Inventor
Christa Hegele-Hartung
Quoc-Lam Cam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to EP99939972A priority Critical patent/EP1098652A2/en
Publication of EP1098652A2 publication Critical patent/EP1098652A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical composition and its use to treat infertility.
  • Meiosis is the unique and ultimate event of germ cells on which sexual reproduction is based. Meiosis comprises two meiotic divisions. During the first division, exchange between maternal and paternal genes take place before the pairs of chromosomes are separated into the two daughter cells. These contain only half the number (1 n) of chromosomes and 2c DNA. The second meiotic division proceeds without a DNA synthesis. This division therefore results in the formation of the hapioid germ cells with only 1c DNA.
  • the meiotic events are similar in the male and female germ cells, but the time schedule and the differentiation processes which lead to ova and to spermatozoa differ profoundly. All female germ cells enter the prophase of the first meiotic division early in life, often before birth, but all are arrested as oocytes later in the prophase
  • Cyclic adenosine 5 ' -monophosphate plays a pivotal role as a second messenger in the signal transduction pathway during meiosis in the oocyte
  • cAMP is generated by the action of adenylate cyclase (AC).
  • AC adenylate cyclase
  • cAMP is degraded by the family of phosphodiesterase enzymes (PDE), which produces inactive second messenger products
  • Hypoxanthine is an inhibitor of cAMP PDE (Eppig, J J et al (1985) Biol Reprod. 33 1041-1049). As such, it can prevent the hydrolysis of oocyte cAMP and thereby maintain elevated levels of cAMP in the oocyte.
  • agents acting upstream or downstream of cAMP are able to increase cAMP levels.
  • activation of AC with forskolin inhibition of PDE with the nonselective 3- isobutyl-1-methyixanth ⁇ ne (lBMX) or inhibition of the oocyte-specific isoform PDE3 with a specific PDE3- ⁇ nhib ⁇ tor, e.g mii ⁇ none, leads to meiotic arrest by maintaining elevated levels of c-AMP within the oocytes (Downs SM and Hunzicker-Dunn M (1995) Dev Biol 172. 72-85, Tsafin A et al (1996) Dev Biol 178. 393-402)
  • a PDE3 specific inhibitor has been described as a contraceptive agent (WO98/10765).
  • the present invention provides a pharmaceutical composition comprising c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility in mammals, particulary in humans, more particulary in females.
  • c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility in mammals, particulary in humans, more particulary in females.
  • the increase of fertility by low dose c-AMP- increasing compounds is surprising since the teaching of the prior art is that c-AMP- increasing compounds are responsible for meiotic arrest and a PDE3 specific inhibitor has even been used as a contraceptive agent.
  • the combination of the low dose cAMP-increasing compounds with at least one meiosis-stimulating compound shows a significantly higher stimulation rate than the meiosis-stimulating compound(s) alone.
  • the invention relates to the use of low dose c-AMP- increasing compounds alone or in combination with at least one meiosis-stimulating compound as active substances for the production of a pharmaceutical composition for the treatment of infertility in mammals, particular in humans, more particularly in females.
  • Low dose c-AMP-increasing compounds alone increase the fertilization rate compared to the control where no compounds were added and the combination of c- AMP-increasing compounds in a low dose with a meiosis-stimulating compound shows an even higher rate of fertilization than the meiosis-stimulating compound alone or the low dose c-AMP-increasing compound alone.
  • the invention relates to the use of low dose c-AMP- increasing compounds alone or in combination with at least one meiosis-stimulating compound to increase the rate of fertilization in a mammal, particularly in humans, more particularly in females.
  • This use may be to regulate the fertilization rate in a fertilization culture media.
  • the invention includes the use of a low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound for the administration to a germ cell.
  • the germ ceil may be an oocyte or a spermatozoon.
  • the invention in another embodiment relates to a method of stimulating meiosis in a mammalian germ ceil comprising administering ex vivo or in vivo or in vitro to a germ cell in need of such a stimulation an effective amount of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound.
  • the germ cell may be an oocyte or a spermatozoon.
  • the invention in a further embodiment relates to a pharmaceutical kit comprising a dosage unit for a c-AMP-increasing compound in low dose and a dosage unit of at least one meiosis-stimulating compound.
  • the c-AMP-increasing compound and the meiosis-stimulating compound may be provided in the same application form or in different application forms.
  • Application forms means e.g. tablets, liquid compositions for injections, paste and others well known in the art.
  • Meiosis-stimulating compounds according to the present invention are all compounds that can activate meiosis. Compounds being known to stimulate meiosis and their synthesis are described, i.e., in WO 96/27658, WO97/00884, WO96/00235, W098/28323 and W098/52965. In preferred embodiments of all modes of the invention the meiosis-stimulating compound is FF-MAS (4,4-dimethyl-5 ⁇ -cholesta- 8,14,24-trien-3 ⁇ -ol).
  • the stimulation rate is at least 40 - 50 %, preferred 50 - 75%, and more preferred 75 - 100 %.
  • Low dose cAMP-increasing compounds according to the present invention is a dose of cAMP-increasing compounds that lead to meiotic maturation without inducing meiotic arrest.
  • the cAMP- increasing compounds are applied in a dose below 3mM, more preferred in a dose of 0.003 - 1 mM, and especially preferred in a dose of 0.1-0.5mM.
  • the cAMP- increasing compounds are purines, unspecific PDE-inhibitors, specific PDE 3 - inhibitors or synthetic membrane permeable cAMP.
  • a purine is e.g. hypoxanthine or adenosine.
  • Unspecific PDE-inhibitors are nonselective inhibitors which inhibit all types of PDEs, e.g. IBMX, theophylline or SQ20,006 (1-ethyl-4-hydrazino-14- pyrazolo-(3,4-b)-pyridine-5-carboxylicacidethyiester).
  • PDE3 inhibitors examples include milrinone, cilostamide, amrinone, enoximone, lixazinone, indolidan and other inhibitors as listed in WO98/10765. This reference also gives the methods of preparation of these compounds.
  • An example for a synthetic membrane permeable cAMP is dibutyryl-c-AMP (dbcAMP).
  • the meiosis-stimulating compound is FF-MAS and the cAMP-increasing compound is a purine, preferably hypoxanthine.
  • compositions may comprise pharmaceutically acceptable excipients well known in the art like carriers, diluents, absorption enhancers, preservatives, buffers, agents for adjusting the osmotic pressure, tablet disintegrating agents and other ingredients which are conventionally used in the art.
  • solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatin, pectin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, low melting waxes and cacao butter.
  • Liquid compositions include sterile solutions, suspensions and emulsions.
  • Such liquid compositions may be suitable for injection or for use in connection with ex vivo, in vivo ,and in vitro fertilization.
  • the liquid compositions may contain other ingredients which are conventionally used in the art, some of which are mentioned in the list above.
  • a composition for transdermal administration of a compound of this invention may be provided in the form of a patch
  • a composition for nasal administration may be provided in the form of a nasal spray in liquid or powder form
  • a composition for intra-vaginal administration may be provided in the form of a tampon or other intra-vaginal devices.
  • the dosage to be administered depends to a large extent on the condition and the size of the subject being treated as well as the frequency of treatment and the route of administration.
  • compositions of the invention are prepared by intimately bringing into association the active compound or compounds with the liquid or solid auxiliary ingredients and then, if necessary, shaping the product into the desired formulation.
  • Example 1 Test of hypoxanthine, FF-MAS and the combination of FF-MAS and hypoxanthine in the oocyte assay
  • Naked oocytes (NO) and cumulus enclosed oocytes (CEO) were isolated from follicles from immature (C57B1/6J x DBA/2J)F ⁇ mice (age 21-24 days), that had received 10 I.U. PMSG i.p. 48h prior to collection.
  • the oocytes were cultured in 4- well multidishes in a modified ⁇ -MEM medium containing 1mg fetuin/ml culture medium. Each well contained 0.4 ml of the oocyte culture medium and 35-45 oocytes.
  • the control and test cultures were made with different concentrations of the compounds to be tested as indicated in the tables.
  • the cultures were kept at 37°C and 100% humidity with 5% C0 2 in the air for 18 hours.
  • Oocytes arrested in meiosis are characterised by an intact nucleus with a prominent nucleolus, known as germinal vesicle (GV).
  • GV germinal vesicle
  • Table 1 Activation of meiosis in oocytes using FF-MAS, low dose hypoxanthine and the combination of FF-MAS + hypoxanthine
  • GVB germinal vesicle breakdown
  • n number of
  • hypoxanthine used was obtained from Sigma, Deisenhofen, Germany. Similar to the control, low dose hypoxanthine (0.4mM) is able to lead to meiotic maturation in most oocytes. However, 3mM hypoxanthine nearly completely prevents meiotic maturation. It is evident that FF-MAS not only when given together with a meiosis - inhibiting dose of hypoxanthine (3mM), but also when given together with low dose hypoxanthine (0.4mM) is able to lead to meiotic maturation in nearly all oocytes.
  • Example 2 Test of hypoxanthine, FF-MAS and the combination of FF-MAS and hypoxanthine in the in-vitro fertilization (IVF) assay
  • GVB germinal vesicle breakdown
  • hypoxanthine used was obtained from Sigma, Deisenhofen, Germany. Oocytes cultured in the presence of 3mM hypoxanthine were unable to get fertilized. 0.4mM hypoxanthine and 10 ⁇ M FF-MAS + 3 mM hypoxanthine increased the fertilization rate of the control group by about 50%. However, the combination of 10 ⁇ M FF-MAS + 0.4 mM hypoxanthine could nearly double the control IVF-rate.

Abstract

The present invention relates to a pharmaceutical composition comprising c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility and to the use of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound to increase the rate of fertilization in a mammal and for the preparation of medicaments. The preferred c-AMP-increasing compound is Hypoxanthine. The meiosis-stimulating compound is FF-MAS (4,4-dimethyl-5alpha-cholest-8,14,24-trien-3beta-ol).

Description

Treatment of Infertility with cAMP-increasing Compounds alone or in combination with at least one Meiosis-stimulating Compound
The present invention relates to a pharmaceutical composition and its use to treat infertility.
Meiosis is the unique and ultimate event of germ cells on which sexual reproduction is based. Meiosis comprises two meiotic divisions. During the first division, exchange between maternal and paternal genes take place before the pairs of chromosomes are separated into the two daughter cells. These contain only half the number (1 n) of chromosomes and 2c DNA. The second meiotic division proceeds without a DNA synthesis. This division therefore results in the formation of the hapioid germ cells with only 1c DNA.
The meiotic events are similar in the male and female germ cells, but the time schedule and the differentiation processes which lead to ova and to spermatozoa differ profoundly. All female germ cells enter the prophase of the first meiotic division early in life, often before birth, but all are arrested as oocytes later in the prophase
(dictyate state) until ovulation after puberty. Thus, from early life the female has a stock of oocytes which is drawn upon until the stock is exhausted. Meiosis in females is not completed until after fertilization, and results in only one ovum and two abortive polar bodies per germ cell. In contrast, only some of the male germ cells enter meiosis from puberty and leave a stem population of germ cells throughout life. Once initiated, meiosis in the male cell proceeds without significant delay and produces 4 spermatozoa.
Only little is known about the mechanisms which control meiosis in the male and in the female. In the oocyte, recent studies indicate that follicular purines, such as hypoxanthine, and adenosine, could be responsible for meiotic arrest (Downs, S.M. et al. (1985), Dev. Biol. 82: 454-458, Eppig, J.J. et al. (1986) Dev. Biol. 119: 313-321 , Downs, S.M. et al. (1993), Mol. Reprod. Dev. 35: 82-94). These purine bases were found in follicular fluid in miilimolar concentrations (Eppig, J.J. et al. (1985) Biol. Reprod. 33: 1041-1049). However, the purine bases induced arrest was reversible. This was provided by experiments in whicn mice and human oocvtes were maintained in meiotic arrest for 24 hours with hypoxanthine followed bv a 16-30 hour culture in inhibitor-free medium (Downs, S.M et al (1986) Garnet Res 15 305-316, Cha. K Y et al (1992) Reprod Fertil. Dev 4 695-701) Nearly 100% of the arrested mice oocytes resumed maturation and, furthermore, the mature oocytes were successfully fertilized and demonstrated complete pre-and post-implantation development These data collectively support the idea that purines such as hypoxanthine and adenosine are physiologically important in the mechanisms controlling meiotic arrest in vivo
Cyclic adenosine 5'-monophosphate (cAMP) plays a pivotal role as a second messenger in the signal transduction pathway during meiosis in the oocyte cAMP is generated by the action of adenylate cyclase (AC). cAMP is degraded by the family of phosphodiesterase enzymes (PDE), which produces inactive second messenger products Hypoxanthine is an inhibitor of cAMP PDE (Eppig, J J et al (1985) Biol Reprod. 33 1041-1049). As such, it can prevent the hydrolysis of oocyte cAMP and thereby maintain elevated levels of cAMP in the oocyte. In addition to hypoxanthine, agents acting upstream or downstream of cAMP are able to increase cAMP levels. By this way activation of AC with forskolin, inhibition of PDE with the nonselective 3- isobutyl-1-methyixanthιne (lBMX) or inhibition of the oocyte-specific isoform PDE3 with a specific PDE3-ιnhibιtor, e.g miiπnone, leads to meiotic arrest by maintaining elevated levels of c-AMP within the oocytes (Downs SM and Hunzicker-Dunn M (1995) Dev Biol 172. 72-85, Tsafin A et al (1996) Dev Biol 178. 393-402)
A PDE3 specific inhibitor has been described as a contraceptive agent (WO98/10765).
The presence of a diffusible meiosis regulating substance was first described (Byskov, A.G et al. (1976) Dev Biol. 52. 193-200) in the fetal mouse gonades. A meiosis activating substance (MAS) was secreted in the fetal mouse ovary in which meiosis was ongoing, and a meiosis preventing substance (MPS) was released from the morphologically differentiated testis with resting, non-meiotic germ cells It was therefore suggested that the relative concentrations of MAS and MPS regulated the beginning, arrest and resumption of meiosis in the male and in the female germ cells (Byskov, A.G and Høyer P E (1994), The Physiology of Reproduction, Knobil, E and Neill.J D (eds ), Raven Press, New York, pp 487-540) A recent article (Byskov, A G et al (1995) Nature 374 559-562) describes the isolation of certain sterols from preovulatory ovarian follicular fluid, defined as FF-MAS, and bull testicular testis, defined as T-MAS, that activate oocyte meiosis. This was confirmed by Grøndahl et al. (1998, Biol. Reprod. in press) showing that de novo synthesized FF-MAS is capable of mediating resumption of meiosis in mice oocytes.
Although the use of MAS improves the rate of fertility compared to the currently applied methods, it is still desirable to increase this rate even further.
This is achieved by the present invention which provides a pharmaceutical composition comprising c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility in mammals, particulary in humans, more particulary in females. The increase of fertility by low dose c-AMP- increasing compounds is surprising since the teaching of the prior art is that c-AMP- increasing compounds are responsible for meiotic arrest and a PDE3 specific inhibitor has even been used as a contraceptive agent. The combination of the low dose cAMP-increasing compounds with at least one meiosis-stimulating compound shows a significantly higher stimulation rate than the meiosis-stimulating compound(s) alone.
In a further embodiment the invention relates to the use of low dose c-AMP- increasing compounds alone or in combination with at least one meiosis-stimulating compound as active substances for the production of a pharmaceutical composition for the treatment of infertility in mammals, particular in humans, more particularly in females. Low dose c-AMP-increasing compounds alone increase the fertilization rate compared to the control where no compounds were added and the combination of c- AMP-increasing compounds in a low dose with a meiosis-stimulating compound shows an even higher rate of fertilization than the meiosis-stimulating compound alone or the low dose c-AMP-increasing compound alone.
In a still further embodiment the invention relates to the use of low dose c-AMP- increasing compounds alone or in combination with at least one meiosis-stimulating compound to increase the rate of fertilization in a mammal, particularly in humans, more particularly in females. This use may be to regulate the fertilization rate in a fertilization culture media.
In another aspect, the invention includes the use of a low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound for the administration to a germ cell. The germ ceil may be an oocyte or a spermatozoon.
In another embodiment the invention relates to a method of stimulating meiosis in a mammalian germ ceil comprising administering ex vivo or in vivo or in vitro to a germ cell in need of such a stimulation an effective amount of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound. The germ cell may be an oocyte or a spermatozoon.
In a further embodiment the invention relates to a pharmaceutical kit comprising a dosage unit for a c-AMP-increasing compound in low dose and a dosage unit of at least one meiosis-stimulating compound. The c-AMP-increasing compound and the meiosis-stimulating compound may be provided in the same application form or in different application forms. Application forms means e.g. tablets, liquid compositions for injections, paste and others well known in the art.
Meiosis-stimulating compounds according to the present invention are all compounds that can activate meiosis. Compounds being known to stimulate meiosis and their synthesis are described, i.e., in WO 96/27658, WO97/00884, WO96/00235, W098/28323 and W098/52965. In preferred embodiments of all modes of the invention the meiosis-stimulating compound is FF-MAS (4,4-dimethyl-5α-cholesta- 8,14,24-trien-3β-ol).
Under a significantly higher stimulation rate of fertilization according to the present invention it is meant that the stimulation rate is at least 40 - 50 %, preferred 50 - 75%, and more preferred 75 - 100 %.
Low dose cAMP-increasing compounds according to the present invention is a dose of cAMP-increasing compounds that lead to meiotic maturation without inducing meiotic arrest. In preferred embodiments of the present invention the cAMP- increasing compounds are applied in a dose below 3mM, more preferred in a dose of 0.003 - 1 mM, and especially preferred in a dose of 0.1-0.5mM.
In specially preferred embodiments of all modes of the invention the cAMP- increasing compounds are purines, unspecific PDE-inhibitors, specific PDE3- inhibitors or synthetic membrane permeable cAMP. A purine is e.g. hypoxanthine or adenosine. Unspecific PDE-inhibitors are nonselective inhibitors which inhibit all types of PDEs, e.g. IBMX, theophylline or SQ20,006 (1-ethyl-4-hydrazino-14- pyrazolo-(3,4-b)-pyridine-5-carboxylicacidethyiester). Examples of specific PDE3 inhibitors are milrinone, cilostamide, amrinone, enoximone, lixazinone, indolidan and other inhibitors as listed in WO98/10765. This reference also gives the methods of preparation of these compounds. An example for a synthetic membrane permeable cAMP is dibutyryl-c-AMP (dbcAMP).
In a further specially preferred embodiments of all modes of the invention the meiosis-stimulating compound is FF-MAS and the cAMP-increasing compound is a purine, preferably hypoxanthine.
As described above the present invention relates in further embodiments to pharmaceutical compositions. The compositions may comprise pharmaceutically acceptable excipients well known in the art like carriers, diluents, absorption enhancers, preservatives, buffers, agents for adjusting the osmotic pressure, tablet disintegrating agents and other ingredients which are conventionally used in the art. Examples of solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatin, pectin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, low melting waxes and cacao butter. Liquid compositions include sterile solutions, suspensions and emulsions. Such liquid compositions may be suitable for injection or for use in connection with ex vivo, in vivo ,and in vitro fertilization. The liquid compositions may contain other ingredients which are conventionally used in the art, some of which are mentioned in the list above. Further, a composition for transdermal administration of a compound of this invention may be provided in the form of a patch, a composition for nasal administration may be provided in the form of a nasal spray in liquid or powder form and a composition for intra-vaginal administration may be provided in the form of a tampon or other intra-vaginal devices.
The dosage to be administered depends to a large extent on the condition and the size of the subject being treated as well as the frequency of treatment and the route of administration.
In general, the compositions of the invention are prepared by intimately bringing into association the active compound or compounds with the liquid or solid auxiliary ingredients and then, if necessary, shaping the product into the desired formulation. The entire disclosure of all applications, patents and publications, cited above and below are hereby incorporated by reference.
The present invention will be illustrated in detail in the following examples. These examples are included for illustrative purposes and should not be considered to limit the present invention.
Examples
Example 1 : Test of hypoxanthine, FF-MAS and the combination of FF-MAS and hypoxanthine in the oocyte assay
Material and Methods:
Naked oocytes (NO) and cumulus enclosed oocytes (CEO) were isolated from follicles from immature (C57B1/6J x DBA/2J)Fι mice (age 21-24 days), that had received 10 I.U. PMSG i.p. 48h prior to collection. The oocytes were cultured in 4- weil multidishes in a modified α-MEM medium containing 1mg fetuin/ml culture medium. Each well contained 0.4 ml of the oocyte culture medium and 35-45 oocytes. The control and test cultures were made with different concentrations of the compounds to be tested as indicated in the tables.
The cultures were kept at 37°C and 100% humidity with 5% C02 in the air for 18 hours.
Oocytes arrested in meiosis are characterised by an intact nucleus with a prominent nucleolus, known as germinal vesicle (GV). Upon reinitiation of meiosis the nucleolus and the nuclear envelope disappear and this is characterised by a breakdown of the GV, which than is called germinal vesicle breakdown (GVB). Results:
Table 1 : Activation of meiosis in oocytes using FF-MAS, low dose hypoxanthine and the combination of FF-MAS + hypoxanthine
Hx = Hypoxanthine NO = naked oocytes GVB = germinal vesicle breakdown n = number of
The hypoxanthine used was obtained from Sigma, Deisenhofen, Deutschland. Similar to the control, low dose hypoxanthine (0.4mM) is able to lead to meiotic maturation in most oocytes. However, 3mM hypoxanthine nearly completely prevents meiotic maturation. It is evident that FF-MAS not only when given together with a meiosis - inhibiting dose of hypoxanthine (3mM), but also when given together with low dose hypoxanthine (0.4mM) is able to lead to meiotic maturation in nearly all oocytes. Example 2: Test of hypoxanthine, FF-MAS and the combination of FF-MAS and hypoxanthine in the in-vitro fertilization (IVF) assay
Material and Methods:
NO and CEO from immature mice (C57B1/6J x DBAJ/2)F! were isolated and cultured under the same conditions as described for the oocyte assay. After 18 hours oocytes that exhibited germinal vesicle breakdown (GVB) were shortly washed in hypoxanthine-free medium and transferred to the insemination dishes prepared in advance, which consisted of a motile sperm preparation from the caudal epididymis of male mice. The dishes were then incubated under defined gas conditions (5% C02) at 37°C in a modified α-MEM IVF-medium. Neither the insemination medium nor the IVF-medium contained hypoxanthine. Examination of the oocytes were carried out 20-22 hours after insemination, in order to check fertilization and to record the number of 2-cell embryos. The percentage fertilization (= fertilization rate) was determined from counts of oocytes that had cleaved into two-cell embryos.
Results:
Table 2: In vitro fertilization rate (IVF-rate) of oocytes cultured with FF-MAS, low dose hypoxanthine and the combination of FF-MAS + hypoxanthine
Hx = hypoxanthine NO = naked oocytes n = number of
GVB = germinal vesicle breakdown
The hypoxanthine used was obtained from Sigma, Deisenhofen, Deutschland. Oocytes cultured in the presence of 3mM hypoxanthine were unable to get fertilized. 0.4mM hypoxanthine and 10μM FF-MAS + 3 mM hypoxanthine increased the fertilization rate of the control group by about 50%. However, the combination of 10μM FF-MAS + 0.4 mM hypoxanthine could nearly double the control IVF-rate.

Claims

Claims
1. A pharmaceutical composition comprising c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility in mammals.
2. Pharmaceutical composition according to claim 1 wherein the mammal is a human.
3. Pharmaceutical composition according to one of the claims 1 or 2 wherein c- AMP-increasing compounds are purines, unspecific PDE-inhibitors, specific PDE3-inhibitors and synthetic membrane permeable cAMP.
4. Pharmaceutical composition according to one of the claims 1 , 2 or 3 wherein the meiosis-stimulating compound is FF-MAS.
5. Pharmaceutical composition according to one of the claims 1-4 wherein the c- AMP-increasing compound is hypoxanthine.
6. Use of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound as active substances for the production of a pharmaceutical composition for the treatment of infertility in mammals.
7. Use according to claim 6, wherein the mammal is a human.
8. Use according to one of the claims 6 or 7, wherein the c-AMP-increasing compounds are used alone.
9. Use according to one of the claims 6, 7 or 8, wherein the c-AMP-increasing compound is selected from the group consisting of purines, unspecific PDE- inhibitors, specific PDE3-inhibitor and synthetic membrane permeable cAMP.
10. Use according to one of the claims 6-9, wherein the c-AMP-increasing compound is hypoxanthine.
11. Use according to one of the claims 6, 7, 9 or 10 , wherein the meiosis- stimulating compound is FF-MAS.
12. Use of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound to increase the rate of fertilization in a mammal.
13. Use according to claim 12, wherein the mammal is a human.
14. Use according to one of the claims 12 or 13 to regulate the fertilization rate in fertilization culture media.
15. Use according to one of the claims 12-14, wherein the c-AMP-increasing compounds are used alone.
16. Use according to one of the claims 12-15, wherein the c-AMP-increasing compound is selected from the group consisting of purines, unspecific PDE- inhibitors, specific PDE3-inhibitors and synthetic membrane permeable cAMP.
17. Use according to one of the claims 12-16, wherein the c-AMP-increasing compound is hypoxanthine.
18. Use according to one of the claims 12-14 or 16-17, wherein the meiosis- stimulating compound is FF-MAS.
19. Use of a low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound for the administration to a germ cell.
20. Use according to claim 19, wherein the germ cell is an oocyte.
21. Use according to claim 19, wherein the germ cell is a spermatozoon.
22. Use according to one of the claims 19, 20 or 21 , wherein c-AMP-increasing compounds are used aione.
23. Use according to one of the claims 19-22, wherein the c-AMP-increasing compound is selected from the group consisting of purines, unspecific PDE- inhibitors, specific PDE3-inhibitors and synthetic membrane permeable cAMP.
24. Use according to one of the claims 19-23, wherein the c-AMP-increasing compound is hypoxanthine.
25. Use according to one of the claims 19-21 or 23-24 wherein the meiosis- stimulating compound is FF-MAS.
26. A method of stimulating meiosis in a mammalian germ cell comprising administering ex vivo or in vivo or in vitro to a germ cell in need of such a stimulation an effective amount of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound.
27. A method according to claim 26, wherein the germ cell is an oocyte
28. A method according to claim 26, wherein the germ cell is a spermatozoon.
29. A method according to one of the claims 26-28, wherein c-AMP-increasing compounds are used alone.
30. A method according to one of the claims 28-31 , wherein c-AMP-increasing compound is selected from the group consisting of purines, unspecific PDE- inhibitors, specific PDE3-inhibitors and synthetic membrane permeable cAMP.
31. A method according to one of the claims 26-30 wherein the c-AMP-increasing compound is hypoxanthine.
32. A method according to one of the claims 26-28, 30 or 31 , wherein the meiosis- stimulating compound is FF-MAS.
33. A pharmaceutical kit comprising a dosage unit for a c-AMP-increasing compound in low dose and a dosage unit of at least one meiosis-stimulating compound.
EP99939972A 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound Withdrawn EP1098652A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99939972A EP1098652A2 (en) 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98250177 1998-05-26
EP98250177 1998-05-26
EP99939972A EP1098652A2 (en) 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
PCT/EP1999/003138 WO1999061010A2 (en) 1998-05-26 1999-05-07 Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound

Publications (1)

Publication Number Publication Date
EP1098652A2 true EP1098652A2 (en) 2001-05-16

Family

ID=8234594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99939972A Withdrawn EP1098652A2 (en) 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound

Country Status (7)

Country Link
EP (1) EP1098652A2 (en)
JP (1) JP2002516272A (en)
KR (1) KR20010043828A (en)
AU (1) AU5408999A (en)
CA (1) CA2333320A1 (en)
NO (1) NO20005954D0 (en)
WO (1) WO1999061010A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023324T2 (en) 1999-09-16 2006-07-20 Novo Nordisk A/S COMPOSITION FOR IN-VITRO FERTILIZATION
US6544166B1 (en) 1999-11-25 2003-04-08 Groendahl Christian Treatment of human infertility
WO2001038493A1 (en) * 1999-11-25 2001-05-31 Novo Nordisk A/S Treatment of human infertility
AU3376501A (en) * 2000-02-25 2001-09-03 Novo Nordisk A/S Improvement of implantation rate
WO2001062258A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate using ff-mas
WO2001076360A2 (en) * 2000-04-06 2001-10-18 Novo Nordisk A/S Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro
EP1147774A1 (en) * 2000-04-20 2001-10-24 Stichting Dienst Landbouwkundig Onderzoek Method for improving the quality of sperm for artificial insemination of animals
JP2003533222A (en) * 2000-05-18 2003-11-11 シエーリング アクチエンゲゼルシャフト Fertilization of aging oocytes
EP1245572A1 (en) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
UA80418C2 (en) 2001-12-14 2007-09-25 Applied Research Systems Methods of inducing ovulation using phosphodiesterase inhibitor as non-polypeptide camp level modulator.and method of collecting oocytes for in vitro fertilization
AU2003203145A1 (en) * 2002-02-22 2003-09-09 Novo Nordisk A/S A transducer of mas signalling
WO2013030302A1 (en) 2011-08-30 2013-03-07 Centre National De La Recherche Scientifique Protein complex comprising mcm8 and mcm9 proteins and their use
GB201117453D0 (en) * 2011-10-10 2011-11-23 Univ Dundee Improved sperm function/activity
CN108531447B (en) * 2018-04-13 2021-11-23 上海市生物医药技术研究院 Compound for regulating sperm motility and assisted reproduction and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196530A3 (en) * 1985-03-26 1989-03-22 CTA Finanz AG Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
CA2214126A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
US5800625A (en) * 1996-07-26 1998-09-01 Cauldron Limited Partnership Removal of material by radiation applied at an oblique angle
CA2199663C (en) * 1997-03-11 2004-08-10 Ruth Miriam Moses In vitro maturation and fertilization of mammalian oocytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9961010A2 *

Also Published As

Publication number Publication date
NO20005954L (en) 2000-11-24
CA2333320A1 (en) 1999-12-02
WO1999061010A3 (en) 2000-04-27
KR20010043828A (en) 2001-05-25
AU5408999A (en) 1999-12-13
JP2002516272A (en) 2002-06-04
WO1999061010A2 (en) 1999-12-02
NO20005954D0 (en) 2000-11-24

Similar Documents

Publication Publication Date Title
EP1098652A2 (en) Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
US5830757A (en) Stimulation of Meiosis
AU764452B2 (en) Method of promoting cervical and vaginal secretions
EP1156821B1 (en) Treatment of infertility
EP1156822B1 (en) Iin vitro method for synchronisation of oocyte maturation
US20080311656A1 (en) Meiosis arrest in oocytes in vitro
EP1235899B1 (en) Treatment of human infertility
US6544166B1 (en) Treatment of human infertility
MXPA00009505A (en) TREATMENT OF INFERTILITY WITH cAMP-INCREASING COMPOUNDS ALONE OR IN COMBINATION WITH AT LEAST ONE MEIOSIS-STIMULATING COMPOUND
Roy et al. In vitro inhibition of trophoblast maturation and expansion of early rat blastocysts by an oestrogen antagonist
Uche‐Nwachi Effect of intramuscular sulfadoxine‐pyrimethamine on pregnant Wistar rats
WO2001062260A2 (en) Improvement of implantation rate
EP1272618A2 (en) Synchronization of the cytoplasmatic and nuclear maturation of oocytes in vitro
WO1997000883A1 (en) Meiosis regulating compounds
US20030153808A1 (en) Implantation rate using ff-mas
WO2001088098A2 (en) Fertilization of aged oocytes
CA2335329A1 (en) Meiosis regulating compounds
MXPA97006565A (en) Stimulation of meio

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010302

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040407